Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

NiKem Research, Chiesi Farmaceutici extend research collaboration

By Drug Discovery Trends Editor | September 6, 2011

Chiesi Farmaceutici and NiKem
Research have announced details of their extended research collaboration within
the respiratory therapeutic area. Since 2001 Chiesi and NiKem have collaborated
on several pre-clinical research projects where NiKem provides design,
synthesis, hit validation, lead optimization, biochemical pharmacology, and
ADMET & PK profiling within different therapeutic areas on a
fee-for-service basis.

The current extension
involves the period 2011 to 2014 through a multimillion multi-FTE-based service
agreement on pre-clinical projects of interest for Chiesi in the respiratory
therapeutic area and, in particular, focused on pathologies such as asthma and
COPD.

“The scientific and
business relationship with Chiesi is rock solid and the current extension
follows 10 years of continuous success for both parties in collaborating to
identify novel compounds eligible to candidate status for clinical development,”
says Giuseppe Giardina, CEO of NiKem.

Paolo Chiesi, R&D Director and Vice-President of Chiesi says: “The
collaboration with NiKem was productive and well run by both parties. The
partnership with a single provider for multiple integrated medicinal chemistry
projects is one of the reasons of this successful partnership. It allows use at
best the resources in biochemical pharmacology and ADMET/PK that should support
medicinal chemistry optimization cycles in a flexible format. NiKem has
demonstrated to rapidly adapt to Chiesi needs from time to time, with the
ultimate goal to deliver successful compounds to the clinic.”

NiKem Research, www.nikemresearch.com


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50